Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Antibiotics are a powerful tool in fighting bacterial infections like strep throat, whooping cough or a urinary tract infection. But they can leave the patient with nausea, diarrhea or an upset ...